Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.

NCT03123627 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant Infection

Interventions

DRUG: New profilaxis
DRUG: Profilaxis recommended

Sponsor

Maimónides Biomedical Research Institute of Córdoba